J.M. Kremer
About
In The Last Decade
J.M. Kremer
27 papers receiving 764 citations
Peers
Comparison fields: 5 of 58
- Rheumatology 551
- Hematology 269
- Immunology 194
- Genetics 169
- Public Health, Environmental and Occupational Health 116
Countries citing papers authored by J.M. Kremer
This map shows the geographic impact of J.M. Kremer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.M. Kremer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.M. Kremer more than expected).
Fields of papers citing papers by J.M. Kremer
This network shows the impact of papers produced by J.M. Kremer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.M. Kremer. The network helps show where J.M. Kremer may publish in the future.
Co-authorship network of co-authors of J.M. Kremer
This figure shows the co-authorship network connecting the top 25 collaborators of J.M. Kremer. A scholar is included among the top collaborators of J.M. Kremer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J.M. Kremer. J.M. Kremer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 4 | |
| 2 | 2 | |
| 3 | 3 | |
| 4 | 4 | |
| 5 | 6 | |
| 6 | 1 | |
| 7 | 9 | |
| 8 | 3 | |
| 9 | Tofacitinib, an Oral Janus Kinase Inhibitor, in Combination with Methotrexate Reduced the Progression of Structural Damage in Patients with Rheumatoid Arthritis: Year 2 Efficacy and Safety Results From a 24-Month Phase 3 Study | 4 |
| 10 | 2 | |
| 11 | 1 | |
| 12 | 71 | |
| 13 | 26 | |
| 14 | 176 | |
| 15 | 232 | |
| 16 | 109 | |
| 17 | Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral weekly methotrexate: association with significant decreases in creatinine clearance and renal clearance of the drug after 6 months of therapy. | 69 |
| 18 | Examination of pharmacokinetic variables in a cohort of patients with rheumatoid arthritis beginning therapy with methotrexate compared with a cohort receiving the drug for a mean of 81 months. | 11 |
| 19 | 11 | |
| 20 | Pharmacokinetics of methotrexate with and without non-steroidal antiinflammatory drug administration | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.